Kazia plans to participate in the GBM AGILE international study as its primary path-to-market strategy for GDC-0084.
Mid caps
Cellmid takes on aging with both consumer products and pharmaceuticals
Cellmid Ltd (ASX:CDY) is a life sciences company focused on developing solutions for conditions...
Medlab Clinical Ltd revealed in December that it had raised $5mln in an oversubscribed share...
Combining new technologies and healthcare expertise, the company’s key offerings include...
Zoetic sells CBD chew pouches under the Chill brand in the US and is launching the brand in the...
Through wholly-owned subsidiaries such as Lyramid, Kinera and Advangen, the company develops and...
Alto Capital investment manager and stock market commentator Tony Locantro updates Proactive on this week's listing of Nyrada Inc (ASX:NYR), a spin-off of Noxopharm Ltd’s (ASX:NOX). He discusses the reasons for the spin-off, including some of the recent and expected trading patterns. Locantro...
Mining
Get our market previews and stories before the main networks.
Not just the FTSE. Read about
opportunities from the whole
equities market.
Hear directors at first-hand
or meet them in person at our events.
Watch IPOs and access on the same terms as the institutions.
